Elsevier Launches New Open Access Journal: Applied and Translational Genomics
Amsterdam, July 30, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Applied and Translational Genomics, an open access journal. The journal is dedicated to publishing articles on applied genomics and translational research.
The completion of the human genome project gave way to research that takes the genetic code and applies it to research that aims to eradicate disease. This applied genomic research is most relevant in the area of translational research, or, the field of research which finds itself between that of basic research and clinical trials. Applied and Translational Genomics serves as a home for this exponentially expanding field of research.
“Like any other scientific and technological field, an important outcome measure of research is its meeting societal expectations in wide ranging domains including economic gains, improving living standards, compatible with socio-cultural and religious practices, keeping consistent with contemporary ethical, moral and legal requirements,” said Dhavendra Kumar, MD, Editor-in-Chief of the journal. “There are several potential areas where rapid advances in scientific understanding and avenues for translational research seriously need to be considered. Applied and Translational Genomics aims to be the premier journal to publish this cutting-edge research.”
Bart Wacek, Executive Publisher Life Sciences at Elsevier added, “We are delighted that we have been able to launch this journal in this important area of scientific research. Applied and Translational Genomics has a broad scope and provides a home for high quality research in the areas that sometimes get caught in between basic research and clinical trials.”
For more information or to submit and article, go to: Applied and Translational Genomics. First articles to be published in the journal are now available through ScienceDirect.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Gwen van der Heide
+ 31 20 485 2594